Cannabinoids beyond THC and CBD — CBN, CBG, CBC, CBDA
The cannabis plant produces over a hundred cannabinoids. THC and CBD get the attention, but the minor cannabinoids are what give each strain its distinctive profile.
THC and CBD dominate the cannabis conversation, but they're only two of roughly a hundred cannabinoids the plant produces. The rest — collectively called minor cannabinoids — make up a small percentage of any given strain but are increasingly studied for their distinct effects. This is an overview, not a prescription.
CBG — cannabigerol
CBG is the precursor cannabinoid — most THC and CBD in the plant start as CBGA (cannabigerolic acid) before enzymes convert them. That means young or harvested-early cannabis has more CBG. Pre-clinical research has explored CBG for inflammatory bowel pathways, glaucoma intraocular pressure, and some antibacterial properties, but the human clinical evidence is still limited. CBG is expensive to produce at scale because most strains convert it away during maturation.
CBN — cannabinol
CBN is the degradation product of THC. When THC oxidises over time, it becomes CBN, which is mildly psychoactive (roughly 10% the potency of THC) and has been anecdotally associated with sedation. Older or poorly-stored cannabis tends to have more CBN. Commercial "CBN for sleep" marketing runs ahead of the clinical evidence — controlled trials for CBN specifically are few.
CBC — cannabichromene
CBC is non-psychoactive and present in most cannabis at low levels. Pre-clinical studies have looked at anti-inflammatory and neurogenesis pathways, but human-level research is early-stage. You'll sometimes see CBC-enriched products marketed alongside CBD.
CBDA — cannabidiolic acid
CBDA is the raw, acidic form of CBD before the plant is heated (decarboxylated). Fresh or raw cannabis preparations are CBDA-rich; heated products convert it to CBD. Some research suggests CBDA has distinct pharmacology — it may be more bioavailable than CBD in certain contexts — but the consumer market is still CBD-dominated.
THCV — tetrahydrocannabivarin
THCV is a minor cannabinoid structurally similar to THC. At low doses it is reportedly non-psychoactive and even slightly anti-psychoactive; at higher doses it behaves THC-like. Some strains are bred specifically for THCV content. Research interest in metabolic applications is active but inconclusive.
What this means for product selection
Most consumer CBD products are CBD-dominant with trace minor cannabinoids. If a label boasts specific CBN, CBG, or CBC content, the COA should verify the actual amounts — otherwise it's marketing copy. For the simpler CBD-vs-THC comparison see our CBD vs THC overview.
A regulatory note
Schedule-0 in South Africa applies specifically to low-dose CBD. Other cannabinoids (THC, THCV at higher doses) fall outside the carve-out and require the Section 21 pathway. Products combining significant THC or synthetic cannabinoids are not consumer goods — they're medicines.